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Abstract
Introduction: Clopidogrel is frequently associated with thrombotic thrombocytopenic purpura, however this drug
is rarely related to severe isolated thrombocytopenia. Pentoxifylline has previously been associated with
thrombocytopenia only once. To the best of our knowledge, this is the first report of severe isolated
thrombocytopenia after therapy with both clopidogrel and pentoxyfilline.
Case presentation: We report the case of a 79-year-old Caucasian man who presented to our facility with
intermittent claudication. He had obliterative arterial disease and started therapy with clopidogrel and
pentoxifylline. His basal platelet count was 194 × 10
9 cells/L. At three days after the start of treatment, our patient
had lower limb petechia and stopped taking clopidogrel and pentoxifylline. His platelet count lowered to 4 × 10
9
cells/L and our patient was admitted to hospital. Our patient had purpura with no other hemorrhages or
splenomegaly. Results of a blood smear were normal, and a bone marrow study showed dysmegakaryopoiesis.
Antiplatelet antibody test results were negative, as were all viral serology tests. Imaging study results were normal.
Our patient was given immunoglobulin but there was no sustained platelet increase, so corticotherapy was started
as the next treatment step. At five months after clopidogrel and pentoxifylline were discontinued, his platelet
count continued increasing even after prednisolone was tapered.
Conclusions: Severe isolated thrombocytopenia may appear as a side effect when using clopidogrel and
pentoxifylline. These drugs are widely used by general physicians, internists, cardiologists and vascular surgeons.
We hope this report will raise awareness of the need to monitor the platelet count in patients taking these drugs.
Introduction
Antithrombotic therapy-related thrombocytopenia has
been extensively described concerning heparin and ticlopi-
dine therapy. Clopidogrel, as ticlopidine, is a thienopyri-
dine derivative and it is more effective and safer than
aspirin in reducing adverse cardiovascular events in
patients with atherosclerosis [1]. Clopidogrel acts by inhi-
biting ADP-induced platelet aggregation and, because of
its efficacy, safety profile and tolerability, it is widely used
by the medical community. It has been associated with
thrombotic thrombocytopenic purpura (TTP) [2]. How-
ever, to the best of our knowledge only three reports have
linked this drug with severe isolated thrombocytopenia
[3-5] and the exact mechanism of hematological dyscrasia
associated with clopidogrel remains unclear. Pentoxifylline
has been used to relieve intermittent claudication. The
precise mode of action of pentoxifylline and the sequence
of events leading to clinical improvement are still to be
determined, but some consider it to be a hemorheological
agent. Pentoxifylline and its metabolites may improve
blood flow by increasing red blood cell deformability and
decreasing blood viscosity, also reducing platelets aggrega-
tion [6]. To the best of our knowledge, there is only one
report of pentoxifylline-associated thrombocytopenia [7].
We report a case of clopidogrel plus pentoxifylline
associated severe isolated thrombocytopenia.
Case presentation
Our patient was a 79-year-old Caucasian man with a med-
ical history of hypertension and type 2 diabetes, controlled
with candesartan (16 mg/day) and diet. About three weeks
before admission to our facility, he visited his general prac-
titioner complaining of intermittent claudication. A lower
limb Doppler ultrasound study revealed occluding disease
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any medium, provided the original work is properly cited.of the left femoral and popliteal sector, with low amplitude
flow in the posterior tibial and peroneal arteries. The study
also showed disease of the lower genicular sector with low
dorsalis pedis flow. Clopidogrel (75 mg/day) and pentoxi-
fylline (400 mg/day) were started due to the obliterative
arterial disease, and our patient was referred to a vascular
surgeon. He had a normal baseline platelet count of 194 ×
10
9 cells/L. On the third day after beginning these drugs,
our patient reported lower limb petechia and stopped tak-
ing them. He had no major bleeding loss. At this time his
platelet count was 147 × 10
9 cells/L. Our patient attended
a vascular consult for the first time, and the vascular sur-
geon requested another platelet count. On the 17th day,
the result was 4 × 10
9 platelets/L. Pseudothrombocytope-
nia was excluded after a peripheral blood smear was per-
formed and our patient was admitted to our internal
medicine ward.
On admission, he had purpura in the lower limbs. His
blood pressure was 170/85 mmHg, heart rate was 60
beats per minute and respiratory rate was 16 breaths
per minute. Consciousness was clear and no neurologi-
cal abnormality was noted. Our patient had no jaundice
or cyanosis. Cardiac and pulmonary observation showed
no abnormalities and he did not have abdominal hepa-
tomegaly or splenomegaly (checked with ultrasound).
Severe isolated thrombocytopenia was confirmed (5 ×
10
9 cells/L), without schistocytes or other abnormalities.
His fibrinogen level was normal, as were his haptoglobin
and complement levels. Antiplatelet antibody test results
were negative. b2-Microglobulin and prostate specific
antigen levels were also within normal ranges. There was
no evidence of recent viral infection. Viral serology test
results, including HIV, were negative. Thoracic, abdom-
inal and pelvic computed tomography scan results were
normal. A bone marrow study was performed showing
megakaryocytes within normal and dysmegakaryopoiesis.
Although clopidogrel and pentoxifylline had been
stopped, our patient had 5 × 10
9 platelets/L on hospital
admission (22nd day) and intravenous immunoglobulin
(IgG) was started (0.4 g/kg/day for two days). His platelet
count increased to 44 × 10
9 platelets/L at five days after
admission (27th day after starting clopidogrel and pentoxi-
fylline), but it subsequently decreased again to 32 × 10
9
platelets/L (30th day). Prednisolone was given (1 mg/kg/
day) and four days later (34th day) his platelet count was
85 × 10
9 cells/L and our patient was discharged (Figure 1).
At one month after clopidogrel and pentoxifylline were dis-
continued, platelet count continued to increase (155 × 10
9
cells/L with 0.25 mg prednisolone/kg/day) (Figure 2).
Prednisolone was tapered over four months and our
patient’s platelet count returned to normal levels.
During his stay at the hospital, our patient’s blood pres-
sure and glycemia were controlled with an adequate diet
with no need for medication. Our patient’s claudication
remains stable and he continues peripheral artery disease
follow-up with a vascular surgeon. Our patient is cur-
rently on exercise therapy and our vascular surgery con-
sultant is currently planning to start therapy with aspirin
(100 mg/day) under close surveillance. Our patient was
not indicated for vascular surgery.
Discussion
There are several possible etiologies for thrombocytope-
nia. Firstly, when a low platelet count is obtained, pseudo-
thrombocytopenia must be excluded. Our patient
presented with petechia, ruling out this option. Secondly,
real thrombocytopenia can be inherited or acquired. Our
patient is a 79-year-old man with previous normal platelet
count, suggesting an acquired form of thrombocytopenia
[8]. Thirdly, acquired thrombocytopenia can be divided in
immune and nonimmune causes. We used antiplatelet
antibodies as diagnostic adjuvant. However, this test lacks
sensibility and interlaboratory reproducibility. Some stu-
dies document positive antiplatelet antibody tests in 10%
to 20% of patients with certain nonimmune caused
thrombocytopenia [9]. Drugs can act as immune cause
Figure 1 Platelet count after the beginning of anti-thrombotic
therapy with clopidogrel and pentoxifylline. The arrows mark
the dates when immunoglobulin and corticotherapy were started.
Figure 2 Platelet count including follow-up after hospital
discharge.
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and induce antiplatelet antibody formation. They can also
cause nonimmune thrombocytopenia, suppressing bone
marrow thrombopoiesis. Unlike in idiopathic thrombocy-
topenic purpura, our patient’s platelet count did not
remain chronically low. Instead it continues rising after
corticotherapy tapering, supporting the drug-associated
etiology.
After stopping clopidogrel plus pentoxifylline and pre-
scribing intravenous IgG and corticosteroid therapy our
patient’s platelet count returned to normal. Full recovery
was maintained without corticosteroids, confirming
drug-related thrombocytopenia.
For patients with peripheral artery occlusive disease
and moderate-to-severe disabling intermittent claudica-
tion who do not respond to exercise therapy, and who
are not candidates for surgical or catheter based interven-
tion, treatment guidelines recommend cilostazol (a type
III phosphodiesterase inhibitor that suppresses platelet
aggregation and is a direct arterial vasodilator). However,
they suggest that clinicians do not use cilostazol in
patients with less disabling claudication, as was the case
in our patient. For such patients an exercise training pro-
gram is recommended and antithrombotic therapy may
modify the natural history of chronic lower-extremity
arterial insufficiency as well as lower the incidence of
associated cardiovascular events. Aspirin will delay the
progression of established arterial occlusive disease (75 to
325 mg/day) and, in patients without clinically manifest
coronary or cerebrovascular disease, it is preferred over
clopidogrel. Pentoxifylline may be considered to treat
patients with intermittent claudication; however, the
anticipated outcome is likelyt ob eo fm a r g i n a lc l i n i c a l
importance. American College of Chest Physicians guide-
lines recommend against its use [10,11].
Conclusions
Clopidogrel and pentoxifylline are widely used by general
physicians, internists, cardiologists and vascular surgeons.
This report raises awareness that severe isolated thrombo-
cytopenia can be a potential side effect in patients medi-
cated with these drugs. The exact mechanism(s) that
caused the severe isolated thrombocytopenia remain
unclear. In this case we cannot know which drug caused
the low platelet count or if it was the association of clopi-
dogrel and pentoxifylline that was responsible for it. No
matter which was the case, physicians should be aware
that, when using these drugs, there is a possibility that
severe thrombocytopenia may appear as a side effect and
platelet count must be monitored.
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